Fresenius Medical Care AG
NYSE•FMS
執行長: Ms. Helen Giza
板塊: Healthcare
行業: Medical - Care Facilities
上市日期: 1996-09-17
Fresenius Medical Care AG provides dialysis and related services for individuals with renal diseases in Germany, North America, and internationally. The company offers dialysis treatment and related laboratory and diagnostic services through a network of outpatient dialysis clinics; materials, training, and patient support services comprising clinical monitoring, follow-up assistance, and arranging for delivery of the supplies to the patient's residence; and dialysis services under contract to hospitals in the United States for the hospitalized end-stage renal disease (ESRD) patients and for patients suffering from acute kidney failure. It also develops, manufactures, and distributes various health care products, including polysulfone dialyzers, hemodialysis machines, peritoneal dialysis cyclers, peritoneal dialysis solutions, hemodialysis concentrates, solutions and granulates, bloodlines, renal pharmaceuticals, systems for water treatment, and acute cardiopulmonary and apheresis products. In addition, the company develops, acquires, and in-licenses renal pharmaceuticals; offers renal medications and supplies to patients at homes or to dialysis clinics; and provides vascular, cardiovascular, endovascular specialty, vascular care ambulatory surgery center, and physician nephrology and cardiology services. The company sells its products to dialysis clinics, hospitals, and specialized treatment clinics directly, as well as through local sales forces, independent distributors, dealers, and sales agents. Fresenius Medical Care AG was incorporated in 1996 and is headquartered in Bad Homburg, Germany.
聯絡資訊
市值
$13.67B
本益比 (TTM)
11.8
14.9
股息率
3.3%
52周最高
$30.46
52周最低
$20.95
52周範圍
排名36Top 31.8%
4.5
F-Score
改良版 Piotroski 分析
基於 10 年期基本面
一般 • 4.5 / 9 分
評分區間 (0-9)
8-9: 價值優異
6-7: 基本面強勁
4-5: 整體穩健
0-3: 表現疲弱
資料區間: 2016-2025
財務儀表板
Q4 2025 數據
營業收入
$5.90B+0.00%
近4季度走勢
每股收益
$0.66+0.00%
近4季度走勢
自由現金流
$656.78M+0.00%
近4季度走勢
2025 Annual 財報亮點
核心亮點
Revenue Growth Strong Total revenue reached €19.63 B, up 2% as reported; Constant Currency revenue grew 5% across segments.
Operating Income Jumps Operating income €1.83 B, up 31% reported, driven by segment growth and FME25+ net savings.
Shareholder Net Income Net income attributable to shareholders €978 M, up 88% in Constant Currency, showing strong profitability improvement.
HVHDF Standard Set Introduced HVHDF into clinical practice in U.S. clinics, planning broader commercial launch in 2026 for advanced therapy.
關注風險
Regulatory Uncertainty High Legislative reform threats, including ACA changes and Loper Bright ruling, create uncertainty for reimbursement models.
Cost Inflation Pressures Increased costs for labor, energy, and raw materials may adversely impact financial condition if not offset by pricing.
Cybersecurity Incident Risk IT systems were attacked in 2023; continuous monitoring needed to safeguard confidential patient and business data.
Reimbursement Rate Decline Government payor reimbursement rates are limited, potentially shifting commercially insured patients to lower-paying systems.
未來展望
FME Reignite Strategy Focus Strategy aims for above-market growth and industry-leading margins, building on portfolio reorganization and innovation.
FME25+ Savings Target Expanded FME25+ Program targets cumulative €1.2 BN sustainable savings by the end of 2027 across operations.
Capital Allocation Framework Framework includes 30% to 40% dividend payout ratio and €1 BN share buyback program completion expected soon.
HVHDF Rollout Planned Committed to replacing entire U.S. installed base with 5008X CAREsystem by end of 2030 to drive therapy adoption.
同行對比
營業收入 (TTM)
$22.15B
$21.31B
$17.36B
毛利率 (最新季度)
100.0%
90.9%
90.6%
關鍵指標
股票代碼 | 市值 | 本益比 (TTM) | 股東權益報酬率 (TTM) | 負債率 |
|---|---|---|---|---|
| RPRX | $20.75B | 27.1 | 11.9% | 45.6% |
| INCY | $19.02B | 14.7 | 29.1% | 1.0% |
| HOLX | $16.97B | 31.4 | 11.0% | 27.5% |
長期趨勢
近4季度
營業收入
淨利
營運現金流
4季度營業收入複合增長率
4.7%
溫和增長
4季度淨利複合增長率
33.7%
盈利能力大幅提升
現金流穩定性
100%
現金流表現優異
深度研究
下次財報:2026年5月4日
每股收益:-
|營業收入:-
財務數據
電話會議
財務報告
新聞
損益表
資產負債表
現金流量表
財務比率
變化率
損益表 | 過去12個月 |
|---|
無資料